Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 9:35 PM ET


Company Overview of Meda Pharmaceuticals Inc.

Company Overview

Meda Pharmaceuticals Inc. provides pharmaceutical products Europe, the United States, and internationally. The company’s portfolio primarily focuses on respiratory, allergy, central nervous system, gastroenterology, musculoskeletal, rheumatology, erectile dysfunction, and women's health products. Its products include inhalation and topical aerosols, tablets, creams, nasal sprays, flavored soluble powders, capsules, rectal and hemorrhoidal foams, gels, oral concentrates, injections, oral and extended-release tablets, chewable melt tablets, softgels, rectal suspensions, and ophthalmic solutions. Meda Pharmaceuticals Inc. was formerly known as MedPointe, Inc. and changed its name to Meda Pharma...

265 Davidson Avenue

Suite 300

Somerset, NJ 08873-4120

United States

Founded in 2001





Key Executives for Meda Pharmaceuticals Inc.

Vice President of Commercial Operations
Chief Executive Officer of Meda Ab
Age: 55
Chief Information Officer and Vice President
Senior Vice President of Business Information & Analytics
Chief Medical Officer and Vice President of Medical & Scientific Affairs
Compensation as of Fiscal Year 2015.

Meda Pharmaceuticals Inc. Key Developments

Meda To Reportedly Sell Meda Pharmaceuticals

Meda AB (OM:MEDA A) intends to sell Meda Pharmaceuticals Inc. Meda is exploring options to sell Meda Pharmaceuticals, which could be worth about $1 billion, Bloomberg reported, citing people familiar with the matter. Meda plans to use the funds to reduce debt and seek other acquisitions, Bloomberg said. Rothschild is advising Meda on the sale process. Reuters added that Meda could not immediately be reached for comment outside regular business hours.

Meda Inc. (US) Announces Executive Chagnes

Ton van't Hullenaar, Executive Vice President will additionally take on the responsibility for Meda Inc. (US). Maria Carell Executive Vice President North America /Australia, and President Meda Inc. (US) resigns from her positions to pursue other opportunities outside of the company. Ton will assume the responsibility as country manager US until a successor has been appointed.

Similar Private Companies By Industry

Company Name Region
Stencor, Inc. United States
Leuchemix, Inc. United States
Intocell Inc. United States
Exigent Pharmaceuticals, Inc. United States, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Meda Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at